Riskpilot← Back to searchSign inGet full accessAnaesthefy AB
ABActiveOrg 5592870371Jägarvägen 7Hospital activities · NACE 8610Est. 20200 employees
Revenue 2025
SEK 0
EBITDA margin
—
-48% vs 2024
Equity ratio
43.6%
Financial strength
Net profit 2025
SEK -6K
-48% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -6K | -48% |
| Net profit | SEK -6K | -48% |
| Total assets | SEK 19K | -23% |
| Equity | SEK 8K | -41% |
| Employees | 0 | — |
Legal name
Anaesthefy AB
Org number
5592870371
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
2 december 2020
Share capital
SEK 25 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-07-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bedriva medicinsk konsultverksamhet där arbetet beräknas domineras av arbete som narkos- och intensivvårdsläkare. Utöver detta eventuell medicinsk konsultverksamhet inom sluten- och primärvård, idrotts- och tävlingsevenemang, skönhetsingrepp- och produkter (hudprodukter såsom exempelvis mjukgörande krämer och salvor), undervisning- och kursverksamhet, företags- och skolhälsovård, IT samt investering i värdepapper, äga och förvalta fast och lös egendom och därmed förenlig verksamhet.
Address
Jägarvägen 7
Email
anaesthefyab@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | — | −7 | −4 | −6 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 0 | 0 | −7 | −4 | −6 |
| Net financials | — | — | — | — | — |
| Profit before tax | 0 | 0 | −7 | −4 | −6 |
| Tax | −0 | — | — | — | — |
| Net profit | 0 | 0 | −7 | −4 | −6 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 25 | 25 | 25 | 25 | 19 |
| Equity | 25 | 25 | 18 | 14 | 8 |
| Long-term debt | 0 | — | 7 | 11 | 11 |
| Short-term debt | 0 | — | — | — | — |
| Total debt | — | — | 7 | 11 | 11 |
EBITDA margin
-586100.0%
This company
15.8%
Market median
-3709594% vs market
20212025
Equity ratio
43.6%
This company
38.2%
Market median
+14% vs market
20212025
Return on equity
-70.2%
This company
18.4%
Market median
-482% vs market
20212025
Net profit margin
-586100.0%
This company
8.1%
Market median
-7235902% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
1.29×
This company
0.62×
Market median
-108% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-08-01 – 2025-07-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-08-01 – 2024-07-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-08-01 – 2023-07-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-08-01 – 2022-07-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-12-01 – 2021-07-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Anaesthefy AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nils Erik Oskar Linné | Board of Directors | 0 companies |
| Maria Caroline Elisabeth Linné | Deputy Board Member | 0 companies |